-transparent.png){kind=logo}
Adverse reactions were evaluated from 45 double-blind controlled clinical trials involving triazolam 0.25 mg (N = 731), triazolam 0.5 mg (N = 2004), flurazepam 30 mg (N = 899), and placebo (N = 1771). Excessive CNS depression was the most frequent adverse effect, reported in 14.2% of trials with triazolam 0.25 mg, 19.5% with triazolam 0.5 mg, 23.9% with flurazepam 30 mg, and 6.4% with placebo. With the exception of orolingual complaints associated with flurazepam, all other categories of adverse reactions were equally or more frequent with placebo than with active medications. Unusual or excessive adverse reactions were not reported.
Related Publications
D J Greenblatt, and
R I Shader, and
M Divoll, and
J S Harmatz
May 1999,
Arzneimittel-Forschung,
D J Greenblatt, and
R I Shader, and
M Divoll, and
J S Harmatz
January 1978,
The Journal of international medical research,
D J Greenblatt, and
R I Shader, and
M Divoll, and
J S Harmatz
May 1975,
Clinical pharmacology and therapeutics,
D J Greenblatt, and
R I Shader, and
M Divoll, and
J S Harmatz
November 1991,
Lancet (London, England),
D J Greenblatt, and
R I Shader, and
M Divoll, and
J S Harmatz
December 1985,
The New Zealand medical journal,
D J Greenblatt, and
R I Shader, and
M Divoll, and
J S Harmatz
September 1974,
Current therapeutic research, clinical and experimental,
D J Greenblatt, and
R I Shader, and
M Divoll, and
J S Harmatz
January 1977,
Journal of clinical pharmacology,
D J Greenblatt, and
R I Shader, and
M Divoll, and
J S Harmatz
July 2012,
Deutsche medizinische Wochenschrift (1946),
D J Greenblatt, and
R I Shader, and
M Divoll, and
J S Harmatz
January 1983,
Sleep,
D J Greenblatt, and
R I Shader, and
M Divoll, and
J S Harmatz
May 2000,
Medizinische Klinik (Munich, Germany : 1983),
